Publication:

Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field

Loading...
Thumbnail Image

Date

2012

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Informa Healthcare
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Valent, Peter, Gerald J Gleich, Andreas Reiter, Florence Roufosse, Peter F Weller, Andrzej Hellmann, Georgia Metzgeroth, et al. 2012. “Pathogenesis and Classification of Eosinophil Disorders: a Review of Recent Developments in the Field.” Expert Review of Hematology 5 (2) (January): 157–176. doi:10.1586/ehm.11.81.

Abstract

Eosinophils and their products play an essential role in the pathogenesis of various reactive and neoplastic disorders. Depending on the underlying disease, molecular defect and involved cytokines, hypereosinophilia may develop and may lead to organ damage. In other patients, persistent eosinophilia is accompanied by typical clinical findings, but the causative role and impact of eosinophilia remain uncertain. For patients with eosinophil-mediated organ pathology, early therapeutic intervention with agents reducing eosinophil counts can be effective in limiting or preventing irreversible organ damage. Therefore, it is important to approach eosinophil disorders and related syndromes early by using established criteria, to perform all appropriate staging investigations, and to search for molecular targets of therapy. In this article, we review current concepts in the pathogenesis and evolution of eosinophilia and eosinophil-related organ damage in neoplastic and non-neoplastic conditions. In addition, we discuss classifications of eosinophil disorders and related syndromes as well as diagnostic algorithms and standard treatment for various eosinophil-related disorders.

Description

Research Data

Keywords

classification, eosinophilic leukemia, FIP1L1-PDGFRA, hypereosinophilia, hypereosinophilic syndromes, targeted therapy

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories